ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Quick Stats
Jul 02, 202656.0
AI Score
HOLD1.0
Volume Ratio
Aug 04, 2026
Next Earnings
15
+ve Days (30d)
15
-ve Days (30d)
IBRX Stock Summary
Last updated Jul 02, 2026
IBRX is currently trading at $9.44, positioned above its 200-day moving average of $5.4, indicating a long-term uptrend. The stock has a 52-week range of $1.95 to $12.43.
Technical Analysis: The 50-day moving average stands at $7.68, which is below the current price, signaling bullish near-term momentum. The RSI (Relative Strength Index) reads 73.393, suggesting the stock is in overbought territory (bullish but caution advised).
Money Flow Indicators: The Chaikin Money Flow (20-day) is 0.15, which is positive, indicating accumulation by institutional investors. Our AI-powered investment score rates IBRX at 56.0/100 with a HOLD recommendation.
IBRX (ImmunityBio, Inc. Common Stock) Indicators
Last updated Jul 02, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 73.393 |
| CMF (20) | 0.15 |
| ROC (10) | 35.05 |
| ADX (14) | 19.354 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | 0.411 |
| AROONOSC (14) | 78.571 |
| WILLAMS %R (14) | -5.489 |
| MFI (14) | 89.441 |
IBRX Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
IBRX Price vs Max Options Open Interest
IBRX Max Change In Options Open Interest
IBRX Options - Sort by Max open Interest (near term)
3rd July 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
IBRX Daily Out of Money Options - Sort by Max open Interest (near term)
3rd July 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
IBRX Daily In the Money Options - Sort by Max open Interest (near term)
3rd July 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
IBRX Most Active Options by Volume(near term)
3rd July 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
ImmunityBio, Inc. Common Stock is above both 50 Day and 200 Day SMA which is considered Bullish.
IBRX Moving Averages Analysis
ImmunityBio, Inc. Common Stock has been above 50 day sma 1 times in last 30 days. Last time it was above 50 day sma was on Jul 02, 2026
ImmunityBio, Inc. Common Stock has been above 200 day sma 1 times in last 30 days. Last time it was above 200 day sma was on Jul 02, 2026
IBRX (ImmunityBio, Inc. Common Stock) Simple Moving Averages
Moving Averages are last updated Jul 02, 2026
| Days | MA |
|---|---|
| 10 | 8.24 |
| 20 | 7.66 |
| 30 | 7.63 |
| 50 | 7.68 |
| 100 | 7.87 |
| 200 | 5.4 |
IBRX Fundamental Analysis
| P/E (Forward) | 0 |
| P/E (Trailing) | -- |
| Market Cap ($) | 9.6 billion |
| Earnings/Share ($) | -0.85 |
| Net Proft Margin (%) | 0 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -0.85 |
| EPS Estimate Next Year ($) | 0.06 |
| WallStreet Target Price ($) | 13 |
| Most Recent Quarter |
ImmunityBio's stock $IBRX has seen a 55% short volume as attempts to suppress it failed. The company's revolutionary NK cell therapy is expected to change the world with more powerful and longer-lasting cells. ImmunityBio holds the patent for m-ceNK cells, which are expected to lead to a new age of immune system harnessing. Dr. Patrick has been working on global expansion, making this a great opportunity for investors. Elon Musk's potential 10% stake in ImmunityBio could cause the stock to skyrocket by 400%.
Updated 2026-07-03 18:00:02